Angel investor
Every published round Nick Hirons took part in, and every parcel of existing shares it bought off another holder. Deals we hold but haven't published yet are not counted.
| Company | Stage | Announced | Amount | Role | Alongside | Sources |
|---|---|---|---|---|---|---|
| Bodd | Unnamed stage | 3 Dec 2025 | $15m | Participant | Startup Daily (Fri 5 Dec 2025), SmartCompany, Startup Daily (Wed 3 Dec 2025) | |
| Bodd | Unnamed stage | 2023 | $5m | Lead | Startup Daily (Fri 5 Dec 2025), SmartCompany, Startup Daily (Wed 3 Dec 2025), Startup Daily (Thu 5 Jan 2023) |
Companies Nick Hirons has backed in a published round, and companies whose existing shares it bought off another holder.
| Company | What it does | First invested | Rounds | Led |
|---|---|---|---|---|
| Bodd | 2023 | 2 | 1 |
Fund closes reported for Nick Hirons, as distinct from the investments it has made.
Companies Nick Hirons has backed that another company then bought. An exit for the holding, not a deal Nick Hirons did.
| Role | Organisation | Sources |
|---|---|---|
| No role recorded yet. Nick Hirons has been mentioned, but not yet attached to an organisation. Know their role? | ||
Stories naming Nick Hirons. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Six Australian startups, including Bodd, Hachiko and Cor, collectively secured about $24 million in fresh backing, while seaweed peer Sea Forest floated on the ASX and jumped in early trade.
Weekly funding roundup covering raises by Bodd, Hachiko, Fremantle Seaweed, Cor, Detail Earth and Recovr, plus seaweed peer Sea Forest's ASX float at a $112 million market capitalisation.
Also Startup Daily
Bodd has banked a $15 million round with Blue Sky Capital leading and Ellerston Capital among backers, funding global expansion and a health push; the deal values the body-scanning company at $110 million.
Melbourne body-scanning startup Bodd raised $5 million led by Candice and Nick Hirons to expand into North American wellness, fashion and pharmaceutical markets and grow its uniform business.